Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
Acute promyelocytic leukemia (APL) cells express a considerable level of CD33, which is the target of gemtuzumab ozogamicin (GO), and a significantly lower level of P-glycoprotein (P-gp). Therefore, GO is predicted to be a successful treatment for APL. In this article, we report on the GO treatment of 2 patients with APL, who had fully relapsed after induction therapy with all-trans retinoic acid (ATRA) following chemotherapy. Both patients had relapsed 3 times and were resistant to reinduction therapy with ATRA. GO (9 mg/m2) was administered on days 1 and 15. After GO treatment, both patients achieved complete hematologic and molecular remission. GO may be another promising agent for the treatment of ATRA-resistant relapsed APL when given as salvage chemotherapy.
Takeshita
Akihiro
A
Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. akihirot@hama-med.ac.jp
Shinjo
Kaori
K
Naito
Kensuke
K
Matsui
Hirotaka
H
Sahara
Naohi
N
Shigeno
Kazuyuki
K
Suzumura
Taeko
T
Horii
Toshinobu
T
Shirai
Naohito
N
Maekawa
Masato
M
Yada
Yoshihiro
Y
Teshima
Hirofumi
H
Takeuchi
Jin
J
Ohnishi
Kazunori
K
Ohno
Ryuzo
R
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000617:Aminoglycosides / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D000079982:Gemtuzumab; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D014212:Tretinoin / Q000008:administration & dosage
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014212:Tretinoin; D000079982:Gemtuzumab